Prof. Dr. ERDEN BANOĞLU

Yayın Ağı

Makaleler 93

1. Enhanced Efficiency of the Microsomal Prostaglandin E₂ Synthase-1 Inhibitor AGU661 in Human Whole Blood by Encapsulation into PLGA-Based Nanoparticles

Dahlke P., Jordan P. M., Klepsch L. C., Ergül A. G., Stumpf S., Hoeppener S., et al.

MOLECULAR PHARMACEUTICS , 2025 (SCI-Expanded)

2. Harnessing structure-activity relationships to repurpose the FLAP inhibitor BRP-7 into potent and selective sEH inhibitors.

Çalışkan K., Karataş M., Jordan P. M., Çalışkan B., Werz O., Banoğlu E.

Bioorganic chemistry , cilt.165, ss.108997, 2025 (SCI-Expanded)

3. Target-specific de novo design of drug candidate molecules with graph-transformer-based generative adversarial networks

Unlu A., Cevrim E., Yigit M. G., Sarigun A., Celikbilek H., Bayram O., et al.

NATURE MACHINE INTELLIGENCE , cilt.7, sa.9, 2025 (SCI-Expanded)

4. Potent soluble epoxide hydrolase inhibitors based on thiazole-5-carboxamide structure with imidazolidinone moiety as a secondary pharmacophore

LENGERLİ D., KOÇ B., Jordan P. M., ÇALIŞKAN K., ÇALIŞKAN B., Werz O., et al.

Bioorganic Chemistry , cilt.163, 2025 (SCI-Expanded)

5. Phenyl-benzyl-ureas with pyridazinone motif: Potent soluble epoxide hydrolase inhibitors with enhanced pharmacokinetics and efficacy in a paclitaxel-induced neuropathic pain model

LENGERLİ D., Bakht A., ÇALIŞKAN K., Dahlke P., BAL N. B., Jordan P. M., et al.

European Journal of Medicinal Chemistry , cilt.290, 2025 (SCI-Expanded)

6. Discovery of novel microsomal prostaglandin E2 synthase 1 (mPGES-1) inhibitors by a structurally inspired virtual screening study

OLĞAÇ A., Jordan P. M., Kretzer C., Werz O., BANOĞLU E.

Journal of Molecular Graphics and Modelling , cilt.136, 2025 (SCI-Expanded)

7. Isoxazole-pyrimidine derivatives as TACC3 inhibitors: A novel modality to targeted cancer therapy

LENGERLİ D., Çalışkan Ö. A., ÇALIŞKAN K., Saatci Ö., Lim C., Vempati S., et al.

Bioorganic Chemistry , cilt.156, 2025 (SCI-Expanded)

8. 2-Phenylbenzothiazoles featuring heteroaryl sulfonamide end-capping substructures as developable mPGES-1 inhibitors

Yalcin T., Jordan P. M., OLĞAÇ A., Dahlke P., GÜR MAZ Z. T., BANOĞLU E., et al.

ARCHIV DER PHARMAZIE , cilt.358, sa.1, 2025 (SCI-Expanded, Scopus)

9. Novel Benzimidazole Derivatives as Potent Inhibitors of Microsomal Prostaglandin E₂ Synthase 1 for the Potential Treatment of Inflammation, Pain, and Fever

Ergul A. G., Jordan P. M., Dahlke P., BAL N. B., OLĞAÇ A., Uludag O., et al.

JOURNAL OF MEDICINAL CHEMISTRY , cilt.67, sa.23, ss.21143-21162, 2024 (SCI-Expanded, Scopus)

10. Tirbanibulin (KX2-391) analog KX2-361 inhibits botulinum neurotoxin serotype A mediated SNAP-25 cleavage in pre- and post-intoxication models in cells

Koc D., ÇALIŞKAN K., Besarat P., BANOĞLU E., KİRİŞ E.

Drug Development Research , cilt.85, sa.6, 2024 (SCI-Expanded)

11. Novel 1,3,4-oxadiazole derivatives as highly potent microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors

Gür Maz T., Dahlke P., Ergül A. G., Olğaç A., Jordan P. M., Çalışkan B., et al.

BIOORGANIC CHEMISTRY , cilt.147, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

12. Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer

Gedik M. E., Saatci O., Oberholtzer N., ÜNER M., Akbulut Caliskan O., Cetin M., et al.

CANCER RESEARCH , cilt.84, sa.9, ss.1475-1490, 2024 (SCI-Expanded) Sürdürülebilir Kalkınma

13. Substituted 1,2,4-Triazoles as Novel and Selective Inhibitors of Leukotriene Biosynthesis Targeting 5-Lipoxygenase-Activating Protein

Olğaç A., Çapan İ., Dahlke P., Jordan P. M., Werz O., Banoglu E.

ACS OMEGA , cilt.8, sa.34, ss.31293-31304, 2023 (SCI-Expanded, Scopus)

14. Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification

Saatci O., Akbulut O., Cetin M., Sikirzhytski V., ÜNER M., LENGERLİ D., et al.

Cell Death and Differentiation , cilt.30, sa.5, ss.1305-1319, 2023 (SCI-Expanded)

15. Design, Synthesis and Evaluation of Aryl-Tailored Oxadiazole-thiones as New Urease Inhibitors

Gür Maz Z. T., Caliskan H. B., Capan İ., Caliskan B., Özçelik B., Banoglu E.

CHEMISTRYSELECT , cilt.8, sa.8, 2023 (SCI-Expanded, Scopus)

16. Benzoxazolone-5-Urea Derivatives as Human Soluble Epoxide Hydrolase (sEH) Inhibitors.

Gür Maz Z. T., Koç B., Jordan P. M., İbiş K., Çalışkan B., Werz O., et al.

ACS OMEGA , cilt.8, sa.2, ss.2445-2454, 2023 (SCI-Expanded, Scopus)

17. The 1,2,3-triazole 'all-in-one' ring system in drug discovery: a good bioisostere, a good pharmacophore, a good linker, and a versatile synthetic tool.

Lengerli D., Ibis K., Nural Y., Banoglu E.

Expert opinion on drug discovery , cilt.17, sa.11, ss.1209-1236, 2022 (SCI-Expanded)

18. Vicinal Diaryl-Substituted Isoxazole and Pyrazole Derivatives with in Vitro Growth Inhibitory and in Vivo Antitumor Activity

Turanll S., NALBAT E., LENGERLİ D., İBİŞ K., Güntekin Ergün S., Akhan Güzelcan E., et al.

ACS Omega , cilt.7, sa.41, ss.36206-36226, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma

19. Quinazoline-4(3H)-one-7-carboxamide Derivatives as Human Soluble Epoxide Hydrolase Inhibitors with Developable 5-Lipoxygenase Activating Protein Inhibition

Turanli S., Ergul A. G., Jordan P. M., Olğaç A., Çalışkan B., Werz O., et al.

ACS OMEGA , cilt.7, sa.41, ss.36354-36365, 2022 (SCI-Expanded, Scopus)

20. Development and molecular modeling studies of new thiadiazole piperazine urea derivatives as potential fatty acid amide hydrolase inhibitors

Gür Maz Z. T., Turanlı S., Çalışkan H. B., Çalışkan B., Banoğlu E.

ARCHIV DER PHARMAZIE , cilt.355, sa.8, ss.1-11, 2022 (SCI-Expanded)

21. Discovery and Optimization of Piperazine Urea Derivatives as Soluble Epoxide Hydrolase (sEH) Inhibitors.

Çapan İ., Jordan P. M., Olğaç A., Çalışkan B., Kretzer C., Werz O., et al.

ChemMedChem , cilt.17, sa.12, 2022 (SCI-Expanded, Scopus)

22. A Series of Thiadiazolyl-Benzenesulfonamides Incorporating an Aromatic Tail as Isoform-Selective, Potent Carbonic Anhydrase II/XII Inhibitors

Banoglu E., Ercanlı T., Gür Maz T., Vullo D., Bonardi A., Gratteri P., et al.

CHEMMEDCHEM , cilt.17, sa.10, 2022 (SCI-Expanded, Scopus)

23. Novel potent benzimidazole-based microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors derived from BRP-201 that also inhibit leukotriene C4 synthase

Ergül A. G., Maz T. G., Kretzer C., Olğaç A., Jordan P. M., Çalışkan B., et al.

European Journal of Medicinal Chemistry , cilt.231, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

24. Ethoxy acetalated dextran-based nanocarriers accomplish efficient inhibition of leukotriene formation by a novel FLAP antagonist in human leukocytes and blood

Kretzer C., Shkodra B., Klemm P., Jordan P. M., Schröder D., Cinar G., et al.

Cellular and Molecular Life Sciences , cilt.79, sa.1, 2022 (SCI-Expanded)

25. Shifting the Biosynthesis of Leukotrienes Toward Specialized Pro-Resolving Mediators by the 5-Lipoxygenase-Activating Protein (FLAP) Antagonist BRP-201

Kretzer C., Jordan P. M., Bilancia R., Rossi A., Maz T. G., BANOĞLU E., et al.

Journal of Inflammation Research , cilt.15, ss.911-925, 2022 (SCI-Expanded, Scopus)

26. Wood's lamp examination of hair and nails related to COVID-19 treatment

Demir B., Cicek D., Turkoglu S., Bozdemir N. Y., Sarikurt F., BANOĞLU E.

DERMATOLOGIC THERAPY , cilt.34, sa.6, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

27. Crystal Structure and Hirshfeld Surface Analysis of 1-(4-Chlorophenyl)-5-{4-[(2-methylphenyl)methoxy]phenyl}-1H-Pyrazole

AYDIN A., AKKURT M., TURANLİ S., BANOĞLU E., Ozcelik N.

X-RAY STRUCTURE ANALYSIS ONLINE , cilt.37, ss.77-79, 2021 (ESCI)

28. Synthesis and biological evaluation of novel isoxazole-piperazine hybrids as potential anti-cancer agents with inhibitory effect on liver cancer stem cells

Ibis K., NALBAT E., ÇALIŞKAN B., KAHRAMAN D. C., Cetin-Atalay R., BANOĞLU E.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , cilt.221, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

29. Simple heteroaryl modifications in the 4,5-diarylisoxazol-3-carboxylic acid scaffold favorably modulates the activity as dual mPGES-1/5-LO inhibitors with in vivo efficacy

Gurses T., OLĞAÇ A., Garscha U., GÜR MAZ Z. T., BAL N. B., Uludag O., et al.

BIOORGANIC CHEMISTRY , cilt.112, 2021 (SCI-Expanded, Scopus)

30. Exploration of anti-tyrosinase effect of Geranium glaberrimum Boiss. & Heldr. with in silico approach and survey of 21 Geranium species

Celikler Ozer O., Erdoğan Orhan İ., Çalışkan B., Senol Deniz F. S., Gokbulut A., Gur Maz T., et al.

JOURNAL OF HERBAL MEDICINE , cilt.27, 2021 (SCI-Expanded, Scopus)

31. Crystal structure and Hirshfeld surface analysis 4-(4-chlorophenyl)-5-methyl-3-{4-[(2-methylphenyl)methoxy]pnenyl}-1,2-oxazole

Aydin A., AKKURT M., TURANLİ S., LENGERLİ D., BANOĞLU E., Ozcelik N. D.

ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS , cilt.77, ss.346-356, 2021 (ESCI)

32. Synthesis and evaluation of antibacterial and antimycobacterial activities of some new pyrazole derivatives

Gür Maz Z. T., Karaca N., Levent S., Çalışkan B., Demirci F., Banoğlu E.

JOURNAL OF RESEARCH IN PHARMACY , cilt.25, sa.5, ss.531-539, 2021 (ESCI)

33. A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate

Akbulut O., Lengerli D., Saatci O., Duman E., ŞEKER U. Ö. Ş., Isik A., et al.

MOLECULAR CANCER THERAPEUTICS , cilt.19, sa.6, ss.1243-1254, 2020 (SCI-Expanded) Sürdürülebilir Kalkınma

34. Encapsulation of the dual FLAP/mPEGS-1 inhibitor BRP-187 into acetalated dextran and PLGA nanoparticles improves its cellular bioactivity

Shkodra-Pula B., Kretzer C., Jordan P. M., Klemm P., Koeberle A., Pretzel D., et al.

JOURNAL OF NANOBIOTECHNOLOGY , cilt.18, sa.1, 2020 (SCI-Expanded)

35. Discovery of Novel 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors by Exploiting a Multistep Virtual Screening Protocol

OLĞAÇ A., Carotti A., Kretzer C., Zergiebel S., Seeling A., Garscha U., et al.

JOURNAL OF CHEMICAL INFORMATION AND MODELING , cilt.60, sa.3, ss.1737-1748, 2020 (SCI-Expanded, Scopus)

36. Evaluation of Cytotoxic Activity of New Benzimidazole-Piperazine Hybrids Against Human MCF-7 and A549 Cancer Cells

ÖZDEMİR A., Thranli S., ÇALIŞKAN B., Arka M., BANOĞLU E.

Pharmaceutical Chemistry Journal , cilt.53, sa.11, ss.1036-1046, 2020 (SCI-Expanded) Sürdürülebilir Kalkınma

37. Benzimidazole derivatives as potent and isoform selective tumor-associated carbonic anhydrase IX/XII inhibitors

Uslu A. G., Maz T. G., Nocentini A., BANOĞLU E., Supuran C. T., ÇALIŞKAN B.

BIOORGANIC CHEMISTRY , cilt.95, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

38. Protective effect of piceatannol and bioactive stilbene derivatives against hypoxia-induced toxicity in H9c2 cardiomyocytes and structural elucidation as 5-LOX inhibitors

Boccellino M., Donniacuo M., Bruno F., Rinaldi B., Quagliuolo L., Ambruosi M., et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , cilt.180, ss.637-647, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

39. A Multi-step Virtual Screening Protocol for the Identification of Novel Non-acidic Microsomal Prostaglandin E-2 Synthase-1 (mPGES-1) Inhibitors

Shekfeh S., ÇALIŞKAN B., Fischer K., Yalcin T., Garscha U., Werz O., et al.

CHEMMEDCHEM , cilt.14, sa.2, ss.273-281, 2019 (SCI-Expanded) Sürdürülebilir Kalkınma

40. Novel Piperazine Amides of Cinnamic Acid Derivatives as Tyrosinase Inhibitors

GÜR MAZ Z. T., ŞENOL DENİZ F. S., Shekfeh S., ERDOĞAN ORHAN İ., BANOĞLU E., ÇALIŞKAN B.

LETTERS IN DRUG DESIGN & DISCOVERY , cilt.16, sa.1, ss.36-44, 2019 (SCI-Expanded, Scopus)

41. Optimisation by design of experiment of benzimidazol-2-one synthesis under flow conditions

Mostarda S., Maz T. G., Piccinno A., Cerra B., Banoğlu E.

Molecules , cilt.24, sa.13, 2019 (SCI-Expanded, Scopus)

42. Synthesis and cellular bioactivities of novel isoxazole derivatives incorporating an arylpiperazine moiety as anticancer agents

ÇALIŞKAN B., NALBAT E., Ibis K., Guzelcan E. A., ATALAY R., BANOĞLU E.

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY , cilt.33, sa.1, ss.1352-1361, 2018 (SCI-Expanded) Sürdürülebilir Kalkınma

43. Structural insight into the optimization of ethyl 5-hydroxybenzo[g] indol-3-carboxylates and their bioisosteric analogues as 5-LO/mPGES-1 dual inhibitors able to suppress inflammation

Bruno F., Errico S., Pace S., Nawrozkij M. B., Mkrtchyan A. S., Guida F., et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , cilt.155, ss.946-960, 2018 (SCI-Expanded, Scopus)

44. Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis

Gür Maz Z. T., Çalışkan B., Banoğlu E.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , cilt.153, ss.34-48, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

45. Crystal structure and Hirshfeld surface analysis of 1-(2,4-dichlorobenzyl)-5-methyl-N-(thiophene-2-sulfonyl)-1H-pyrazole-3-carboxamide

Aydın A., Akkurt M., Gür Maz Z. T., Banoğlu E.

ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS , cilt.74, ss.747-757, 2018 (ESCI, Scopus)

46. Identification of multi-target inhibitors of leukotriene and prostaglandin E-2 biosynthesis by structural tuning of the FLAP inhibitor BRP-7

GÜR MAZ Z. T., ÇALIŞKAN B., Garscha U., OLĞAÇ A., Schubert U. S., Gerstmeier J., et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , cilt.150, ss.876-899, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

47. Crystal structure and Hirshfeld surface analysis of methyl 1-(2,4-dichlorobenzyl)-5-methyl-1H-pyrazole-3-carboxylate

Aydın A., Akkurt M., Gür Maz Z. T., Banoğlu E.

European Journal of Chemistry , cilt.9, sa.4, ss.347-352, 2018 (Hakemli Dergi)

48. Pteryxin - A promising butyrylcholinesterase-inhibiting coumarin derivative from Mutellina purpurea

ERDOĞAN ORHAN İ., ŞENOL DENİZ F. S., Shekfeh S., Skalicka-Wozniak K., BANOĞLU E.

FOOD AND CHEMICAL TOXICOLOGY , cilt.109, ss.970-974, 2017 (SCI-Expanded, Scopus)

49. The potential role of in silico approaches to identify novel bioactive molecules from natural resources

Olğaç A., Erdoğan Orhan İ., Banoğlu E.

FUTURE MEDICINAL CHEMISTRY , cilt.9, sa.14, ss.1663-1684, 2017 (SCI-Expanded, Scopus)

50. BRP-187: A potent inhibitor of leukotriene biosynthesis that acts through impeding the dynamic 5-lipoxygenase/5-lipoxygenase-activating protein (FLAP) complex assembly

Garscha U., Voelker S., Pace S., Gerstmeier J., Emini B., Liening S., et al.

BIOCHEMICAL PHARMACOLOGY , cilt.119, ss.17-26, 2016 (SCI-Expanded)

51. Synthesis and biological evaluation of C(5)-substituted derivatives of leukotriene biosynthesis inhibitor BRP-7

Levent S., Gerstmeier J., Olğaç A., Nikels F., Garscha U., Carotti A., et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , cilt.122, ss.510-519, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

52. 4,5-Diarylisoxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP)

Banoğlu E., Celikoglu E., Voelker S., Olğaç A., Gerstmeier J., Garscha U., et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , cilt.113, ss.1-10, 2016 (SCI-Expanded, Scopus)

53. Crystal structure and DFT calculations of 5-(4-Chlorophenyl)-1-(6-methoxypyridazin-3-yl)-1 H-pyrazole-3-carboxylic acid

ALAŞALVAR C., SOYLU M. S., ÜNVER H., OCAK İSKELELİ N., YILDIZ M., Ciftci M., et al.

SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY , cilt.132, ss.555-562, 2014 (SCI-Expanded)

54. Synthesis and preliminary mechanistic evaluation of 5-(p-tolyl)-1-(quinolin-2-yl)pyrazole-3-carboxylic acid amides with potent antiproliferative activity on human cancer cell lines

Pirol S. C., ÇALIŞKAN B., Durmaz I., ATALAY R., BANOĞLU E.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , cilt.87, ss.140-149, 2014 (SCI-Expanded)

55. The novel benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP)

Pergola C., Gerstmeier J., Moench B., Caliskan B., Luderer S., Weinigel C., et al.

British Journal of Pharmacology , cilt.171, sa.12, ss.3051-3064, 2014 (SCI-Expanded)

56. Synthesis, biological evaluation and molecular docking studies of trans-indole-3-acrylamide derivatives, a new class of tubulin polymerization inhibitors

Baytaş S., Inceler N., Yilmaz A., Olğaç A., Menevse S., Banoğlu E., et al.

BIOORGANIC & MEDICINAL CHEMISTRY , cilt.22, sa.12, ss.3096-3104, 2014 (SCI-Expanded, Scopus)

57. Chromatographic separation and biological evaluation of benzimidazole derivative enantiomers as inhibitors of leukotriene biosynthesis

Sardella R., Levent S., Ianni F., ÇALIŞKAN B., Gerstmeier J., Pergola C., et al.

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS , cilt.89, ss.88-92, 2014 (SCI-Expanded)

58. Pyrazole derivatives as inhibitors of arachidonic acid-induced platelet aggregation

Levent S., ÇALIŞKAN B., Ciftci M., ÖZKAN Y., Yenicesu I., ÜNVER H., et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , cilt.64, ss.42-53, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma

59. Synthesis and evaluation of analgesic, anti-inflammatory, and anticancer activities of new pyrazole-3(5)-carboxylic acid derivatives

ÇALIŞKAN B., Yilmaz A., Evren I., Menevse S., Uludag O., BANOĞLU E.

MEDICINAL CHEMISTRY RESEARCH , cilt.22, sa.2, ss.782-793, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma

60. Overview of recent drug discovery approaches for new generation leukotriene A(4) hydrolase inhibitors

ÇALIŞKAN B., BANOĞLU E.

EXPERT OPINION ON DRUG DISCOVERY , cilt.8, sa.1, ss.49-63, 2013 (SCI-Expanded)

61. Identification of novel benzimidazole derivatives as inhibitors of leukotriene biosynthesis by virtual screening targeting 5-lipoxygenase-activating protein (FLAP)

BANOĞLU E., ÇALIŞKAN B., Luderer S., EREN G., Ozkan Y., Altenhofen W., et al.

BIOORGANIC & MEDICINAL CHEMISTRY , cilt.20, sa.12, ss.3728-3741, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma

62. Serum interleukin-16 levels in patients with nasal polyposis.

Keseroglu K., BANOĞLU E., Kizil Y., AYDİL U., IŞIK GÖNÜL İ., Yilmaz M., et al.

The Laryngoscope , cilt.122, sa.5, ss.961-4, 2012 (SCI-Expanded)

63. From Molecular Docking to 3D-Quantitative Structure-Activity Relationships (3D-QSAR): Insights into the Binding Mode of 5-Lipoxygenase Inhibitors

EREN G., Macchiarulo A., BANOĞLU E.

MOLECULAR INFORMATICS , cilt.31, sa.2, ss.123-134, 2012 (SCI-Expanded)

64. Pyrazol-3-propanoic acid derivatives as novel inhibitors of leukotriene biosynthesis in human neutrophils

ÇALIŞKAN B., Luderer S., Ozkan Y., Werz O., BANOĞLU E.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , cilt.46, sa.10, ss.5021-5033, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma

65. Synthesis, antioxidant and antimicrobial evaluation of simple aromatic esters of ferulic acid

Ergun B., ÇOBAN T., Onurdag F. K., BANOĞLU E.

Archives of Pharmacal Research , cilt.34, sa.8, ss.1251-1261, 2011 (SCI-Expanded)

66. Stable ester and amide conjugates of some NSAIDs as analgesic and antiinflammatory compounds with improved biological activity

ULUDAĞ M. O., Ergun B., Alkan D. A., Ercan N., Ozkan G. Y., BANOĞLU E.

Turkish Journal of Chemistry , cilt.35, sa.3, ss.427-439, 2011 (SCI-Expanded)

67. Synthesis, biological evaluation, and docking studies of novel heterocyclic diaryl compounds as selective COX-2 inhibitors

EREN G., Unlu S., Nunez M., Labeaga L., Ledo F., Entrena A., et al.

BIOORGANIC & MEDICINAL CHEMISTRY , cilt.18, sa.17, ss.6367-6376, 2010 (SCI-Expanded)

68. Amide derivatives of [6-acyl-2-benzothiazolinon-3-yl] acetic acids as potential analgesic and anti-inflammatory compounds

ÖNKOL T., BANOĞLU E., DÜNDAR Y., Kupeli E., Sahin M. F.

MEDICINAL CHEMISTRY RESEARCH , cilt.19, sa.1, ss.11-24, 2010 (SCI-Expanded)

69. Carbon Nanotubes to Deliver Drug Molecules

İLBASMIŞ TAMER S., Yilmaz S., BANOĞLU E., Degim I. T.

JOURNAL OF BIOMEDICAL NANOTECHNOLOGY , cilt.6, sa.1, ss.20-27, 2010 (SCI-Expanded)

70. Synthesis of 1,5-diarylpyrazol-3-propanoic acids towards inhibition of cyclooxygenase-1/2 activity and 5-lipoxygenase-mediated LTB4 formation

Ergun B., Teresa Nunez M., Labeaga L., Ledo F., Darlington J., Bain G., et al.

Arzneimittel-Forschung/Drug Research , cilt.60, sa.8, ss.497-505, 2010 (SCI-Expanded)

71. Synthesis and biological evaluation of 4,5-diphenyloxazolone derivatives on route towards selective COX-2 inhibitors

DÜNDAR Y., Unlu S., BANOĞLU E., Entrena A., Costantino G., Nunez M., et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , cilt.44, sa.5, ss.1830-1837, 2009 (SCI-Expanded)

72. Screening and evaluation of antioxidant activity of some pyridazine derivatives

Caliskan-Erguen B., Suekueroglu M. K., ÇOBAN T., BANOĞLU E., SÜZEN S.

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY , cilt.23, sa.2, ss.225-229, 2008 (SCI-Expanded)

73. Synthesis, characterization and preliminary screening of regioisomeric 1-(3-pyridazinyl)-3-arylpyrazole and 1-(3-pyridazinyl)-5-arylpyrazole derivatives towards cyclooxygenase inhibition

Unlu S., BANOĞLU E., Ito S., Niiya T., EREN G., Okcelik B., et al.

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY , cilt.22, sa.3, ss.351-361, 2007 (SCI-Expanded)

74. Synthesis of the amide derivatives of 3-[1-(3-pyridazinyl)-5-phenyl-1H-pyrazole-3-yl]propanoic acids as potential analgesic compounds

BANOĞLU E., Sukuroglu M. K., Ergun B., BAYTAŞ S., Aypar E., Aark M.

TURKISH JOURNAL OF CHEMISTRY , cilt.31, sa.6, ss.677-687, 2007 (SCI-Expanded)

75. Screening and evaluation of rat kidney aldose reductase inhibitory activity of some pyridazine derivatives

Sukuroglu M. K., Caliskan-Ergun B., Das-Evcimen N., Sarikaya M., Banoğlu E., Suzen S.

MEDICINAL CHEMISTRY RESEARCH , cilt.15, ss.443-451, 2007 (SCI-Expanded) Sürdürülebilir Kalkınma

76. Synthesis and analgesic activity of some 4,6-disubstituted-3(2H)-pyridazinone derivatives

Sukuroglu M. K., Kupeli E., BANOĞLU E., Unlu S., Yesilada E., Sahin M. F.

ARZNEIMITTELFORSCHUNG-DRUG RESEARCH , cilt.56, sa.5, ss.337-345, 2006 (SCI-Expanded)

77. Synthesis, analgesic, and anti-inflammatory activities of [6-(3,5-dimethyl-4-chloropyrazole-1-yl)-3(2H-pyridazinon-2-yl]acetamides

Sukuroglu M. K., Ergun B., Unlu S., Sahin M., Kupeli E., Yesilada E., et al.

ARCHIVES OF PHARMACAL RESEARCH , cilt.28, sa.5, ss.509-517, 2005 (SCI-Expanded)

78. Synthesis of amide derivatives of [6-(3,5-dimethylpyrazol-1-yl)-3(2H)- pyridazinone-2-yl]acetic acid and their analgesic and anti-inflammatory properties

BANOĞLU E., Akoglu C., Unlu S., Ergun B., Kupeli E., Yesilada E., et al.

Arzneimittel-Forschung/Drug Research , cilt.55, sa.9, ss.520-527, 2005 (SCI-Expanded)

79. Amide derivatives of [6-(5-methyl-3-phenylpyrazole-1-yl)-3(2H)pyridazinone-2-yl]acetic acids as potential a analgesic and anti-inflammatory compounds

BANOĞLU E., Akoglu C., Unlu S., Kupeli E., Yesilada E., Sahin E.

ARCHIV DER PHARMAZIE , cilt.337, sa.1, ss.7-14, 2004 (SCI-Expanded)

80. Investigations of new pyridazinone derivatives for the synthesis of potent analgesic and anti-inflammatory compounds with cyclooxygenase inhibitory activity

Okcelik B., Unlu S., BANOĞLU E., Kupeli E., Yesilada E., Sahin M.

ARCHIV DER PHARMAZIE , cilt.336, sa.9, ss.406-412, 2003 (SCI-Expanded)

81. Amide derivatives of [5-chloro-6-(2-chloro/fluorobenzoyl)-2-benzoxazolinone-3-yl]acetic acids as potential analgesic and anti-inflammatory compounds

BANOĞLU E., Okcelik B., Kupeli E., Unlu S., Yesilada E., Amat M., et al.

ARCHIV DER PHARMAZIE , cilt.336, ss.251-257, 2003 (SCI-Expanded)

82. Synthesis of new 4-(5-chloro-2-oxo-3H-benzoxazol-3-yl)butanamide derivatives and their analgesic and anti-inflammatory properties

Gulcan H., Unlu S., BANOĞLU E., Sahin M., Kupeli E., Yesilada E.

TURKISH JOURNAL OF CHEMISTRY , cilt.27, sa.4, ss.467-476, 2003 (SCI-Expanded)

83. Sulfation of indoxyl by human and rat aryl (phenol) sulfotransferases to form indoxyl sulfate

BANOĞLU E., King R.

EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS , cilt.27, sa.2, ss.135-140, 2002 (SCI-Expanded)

84. Hepatic microsomal metabolism of indole to indoxyl, a precursor of indoxyl sulfate

BANOĞLU E., Jha G., King R.

EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS , cilt.26, sa.4, ss.235-240, 2001 (SCI-Expanded)

85. Simultaneous determination of paracetamol and methocarbamol in tablets by ratio spectra derivative spectrophotometry and LC

Erk N., Ozkan Y., BANOĞLU E., Ozkan S., Senturk Z.

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS , cilt.24, sa.3, ss.469-475, 2001 (SCI-Expanded)

86. Current status of the cytosolic sulfotransferases in the activation of promutagens and procarcinogens metabolic

BANOĞLU E.

CURRENT DRUG METABOLISM , cilt.1, sa.1, ss.1-30, 2000 (SCI-Expanded)

87. Dissolution tests of benazepril-HCl and hydrochlorothiazide in commercial tablets: comparison of spectroscopic and high performance liquid chromatography methods

BANOĞLU E., Ozkan Y., Atay O.

FARMACO , cilt.55, ss.477-483, 2000 (SCI-Expanded)

88. Noradrenaline and nitrite-nitrate concentrations in the contralateral testes during ipsilateral spermatic cord torsion is the presence or absence of a testis and epididymis

TANYEL F. C., Aydin A., BANOĞLU E., Isimer A., Buyukpamukcu N.

BJU INTERNATIONAL , cilt.83, sa.7, ss.833-836, 1999 (SCI-Expanded)

89. Importance of peri-interactions on the stereospecificity of rat hydroxysteroid sulfotransferase STa with 1-arylethanols

BANOĞLU E., Duffel M.

CHEMICAL RESEARCH IN TOXICOLOGY , cilt.12, sa.3, ss.278-285, 1999 (SCI-Expanded)

90. alpha-Hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts

Shibutani S., Dasaradhi L., Terashima I., BANOĞLU E., Duffel M.

CANCER RESEARCH , cilt.58, sa.4, ss.647-653, 1998 (SCI-Expanded)

91. Studies on the interactions of chiral secondary alcohols with rat hydroxysteroid sulfotransferase STa

BANOĞLU E., Duffel M.

DRUG METABOLISM AND DISPOSITION , cilt.25, sa.11, ss.1304-1310, 1997 (SCI-Expanded)

92. Influence of substrate structure on the catalytic efficiency of hydroxysteroid sulfotransferase STa in the sulfation of alcohols

Chen G., BANOĞLU E., Duffel M.

CHEMICAL RESEARCH IN TOXICOLOGY , cilt.9, sa.1, ss.67-74, 1996 (SCI-Expanded)

93. Studies on some 2-substituted benzimidazole derivatives and their antimicrobial activity

BANOĞLU E., Abbasoglu U., ŞAHİN M. G.

Gazi Universitesi Eczacilik Fakultesi Dergisi , cilt.10, sa.1, ss.1-13, 1993 (Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 81

1. EVALUATION OF NOVEL THIAZOLE-5-CARBOXAMIDE-IMIDAZOLIDINONE DERIVATIVES AS POTENT HUMAN SOLUBLE EPOXIDE HYDROLASE INHIBITORS

LENGERLİ D., KOÇ B., JORDAN P. M., ÇALIŞKAN K., ÇALIŞKAN B., WERZ O., et al.

59th International Conference on Medicinal Chemistry (RICT 2025), Orleans, Fransa, 02 Temmuz 2025, (Özet Bildiri)

2. Vicinal Diaryl-Substituted Compounds: Promising Therapeutics for Breast Cancer

NALBAT E., GÜNTEKİN ERGÜN S., TURANLI S., LENGERLİ D., ÇALIŞKAN B., BANOĞLU E., et al.

2024 Annual Congress of the European Association for Cancer Research (EACR 2024), Rotterdam, Hollanda, 10 - 13 Haziran 2024, (Özet Bildiri)

3. Identifying the interactome of TACC3, a major driver in aggressive cancer cells with centrosome amplification

Saatci O., Akbulut O., Cetin M., Sikirzhytski V., ÜNER M., LENGERLİ D., et al.

San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 5 - 09 Aralık 2023, (Özet Bildiri)

4. PYRIDAZINYL-PHENYL BENZYL UREA DERIVATIVES AS HUMAN SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS

Bakht A., LENGERLİ D., Jordan P. M., İBİŞ K., ÇALIŞKAN B., Werz O., et al.

Medicinal Chemistry Frontiers 2024, Utrecht, Hollanda, 08 Nisan 2024, (Özet Bildiri)

5. Targeting hepatocellular carcinoma: evaluation of vicinal diaryl isoxazole and pyrazole derivatives with implications for oxidative stress and senescence-mediated anti-tumor mechanisms

Nalbat E., Akhan Güzelcan E., Turanlı S., Lengerli D., Çalışkan B., Banoğlu E., et al.

EASL Liver Cancer Summit 2024, Rotterdam, Hollanda, 22 - 24 Şubat 2024, ss.76, (Özet Bildiri)

6. Exploring novel vicinal diaryl-substituted isoxazole and pyrazole derivatives as cytotoxic compounds for targeting breast cancer: Mechanisms and therapeutic potential

NALBAT E., GÜNTEKİN ERGÜN S., TURANLI S., LENGERLİ D., ÇALIŞKAN B., BANOĞLU E., et al.

XVIII. Tıbbi Biyoloji ve Genetik Kongresi, Ankara, Türkiye, 26 - 29 Ekim 2023, (Özet Bildiri)

7. Unveiling Novel Leukotriene B4 Receptor (BLT1R) Antagonists and Their Binding Characteristics Through Combined Strategies

OLĞAÇ A., CAROTTI A., BANOĞLU E.

Gordon Research Conference on Computer Aided Drug Design, Vermont, Amerika Birleşik Devletleri, 16 - 21 Temmuz 2023, (Özet Bildiri)

8. A Tale of Two 5-Lipoxygenase Activating Protein (FLAP) Inhibitors

OLĞAÇ A., TURANLI S., ÇAPAN İ., Dahlke P., ERGÜL A. G., Jordan P. M., et al.

Gordon Research Seminar on Computer Aided Drug Design, Vermont, Amerika Birleşik Devletleri, 15 - 16 Temmuz 2023, (Özet Bildiri)

9. A journey from selective FLAP inhibitor to selective mPGES-1 inhibitor: A new therapeutic modality for reducing inflammation and pain

BANOĞLU E., ÇALIŞKAN B., ERGÜL A. G., GÜR MAZ Z. T., OLĞAÇ A., JORDAN P. M., et al.

8th International Bahçeşehir University (BAU) Drug Design Congress, İstanbul, Türkiye, 15 - 17 Aralık 2022, (Özet Bildiri)

10. Identification of Novel Microsomal Prostaglandin E2 Type 1 (mPGES-1) Inhibitors by Conducting Structure-based Virtual Screening

Olğaç A., Carotti A., Jordan P. M., Kretzer C., Werz O., Banoğlu E.

International Bioinformatics Conference (IBC 2022), Tanjah, Fas, 8 - 09 Ekim 2022, ss.17, (Özet Bildiri)

11. IDENTIFICATION OF NOVEL MICROSOMAL PROSTAGLANDIN E2 TYPE 1 (mPGES-1) INHIBITORS BY CONDUCTING STRUCTURE-BASED VIRTUAL SCREENING

OLĞAÇ A., Carotti A., Jordan P. M., Kretzer C., Werz O., BANOĞLU E.

23rd European Symposium on Quantitative Structure-Activity Relationship (EuroQSAR), Heidelberg, Almanya, 26 Eylül 2022, (Özet Bildiri)

12. Design, Synthesis and Biological Evaluation Of Novel Imidazolidinone-Thiazole Amide Hybrids As Inhibitors Of Human Soluble Epoxide Hydrolase

İBİŞ K., LENGERLİ D., JORDAN P., ÇALIŞKAN B., WERZ O., BANOĞLU E.

9th EFMC Young Medicinal Chemists' Symposium, Nice, Fransa, 08 Eylül 2022, (Özet Bildiri)

13. Novel Microsomal Prostaglandin E2 Synthase-1 (MPGES-1) Inhibitors as a New Modality To Treat Inflammation

ÇALIŞKAN B., ERGÜL A. G., GÜR MAZ Z. T., KRETZER C., OLĞAÇ A., JORDAN P. M., et al.

XXVll EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2022), Nice, Fransa, 4 - 08 Eylül 2022, (Özet Bildiri)

14. STUDIES ON THE SYNTHESIS AND ANTICANCER POTENTIAL OF NOVEL 2,4-DIAMINOPYRIMIDINE DERIVATIVES

Lengerli D., Akbulut Çalışkan Ö., Çalışkan B., Şahin Ö., Banoğlu E.

The 9th Young Medicinal Chemist Symposium (EFMC-YMCS 2022), Nice, Fransa, 8 - 09 Eylül 2022, (Özet Bildiri)

15. NOVEL BENZOTHIAZOLE DERIVATIVESAS MICROSOMAL PROSTAGLANDINE E2SYNTHASE-1 (mPGES-1) INHIBITORS

YALÇIN T., GÜR MAZ Z. T., KRETZER C., ÇALIŞKAN B., WERZ O., BANOĞLU E.

9th EFMC Young Medicinal Chemists' Symposium (EFMC-YMCS 2022), Nice, Fransa, 8 - 09 Eylül 2022, (Özet Bildiri)

16. Evaluation of Oxadiazole Derivatives as Promising Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitors

GÜR MAZ Z. T., ERGÜL A. G., JORDAN P. M., ÇALIŞKAN B., WERZ O., BANOĞLU E.

XXVll EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2022), Nice, Fransa, 4 - 08 Eylül 2022, (Özet Bildiri)

17. Karaciğer Kanseri Kök Hücreleri Üzerinde İnhibitör Etkiye Sahip, Potansiyel Antikanser Ajanlar Olarak Yeni İzoksazol-Piperazin Hibritlerinin Sentezi Ve Biyolojik Olarak Değerlendirilmesi

İBİŞ K., NALBAT E., ÇALIŞKAN B., ATALAY R., BANOĞLU E.

VI. Ulusal Farmasötik Kimya Kongresi, İstanbul, Türkiye, 26 - 29 Ağustos 2022, (Özet Bildiri)

18. Benzimidazol türevi öncü bileşiğin in vivo analjezik ve antiinflamatuvar etkilerinin araştırılması

Kaptanoğlu Y., GÜR MAZ Z. T., BAL N. B., BANOĞLU E., ULUDAĞ M. O.

VI. Ulusal Farmasötik Kimya Kongresi, İstanbul, Türkiye, 26 - 29 Ağustos 2022, ss.199-201, (Özet Bildiri)

19. Bazı Visinal Diaril Heterosiklik Bileşiklerin Antikanser Aktivitelerinin Araştırılması

Turanli S., Nalbat E., Akhan Güzelcan E., Atalay R., Çalışkan B., Banoğlu E.

VI.Ulusal Farmasötik Kimya Kongresi, İstanbul, Türkiye, 26 - 29 Ağustos 2022, ss.42-44, (Özet Bildiri)

20. TACC3 İnhı̇bı̇törü Yenı̇ 2,4-Dı̇amı̇nopı̇rı̇mı̇dı̇n Türevlerı̇nı̇n Sentezı̇, Antı̇-Kanser Etkı̇ Potansı̇yellerı̇ ve İlaç Benzerı̇ Özellı̇klerı̇nı̇n Değerlendı̇rı̇lmesı̇ Üzerı̇ne Çalışmalar

LENGERLİ D., AKBULUT ÇALIŞKAN Ö., ÇALIŞKAN B., ŞAHİN Ö., BANOĞLU E.

VI. Ulusal Farmasötik Kimya Kongresi, İstanbul, Türkiye, 26 Ağustos 2022, (Özet Bildiri) Sürdürülebilir Kalkınma

21. KARACİĞER KANSERİ KÖK HÜCRELERİ ÜZERİNDE İNHİBİTÖR ETKİYE SAHİP, POTANSİYEL ANTİKANSER AJANLAR OLARAK YENİ İZOKSAZOL-PİPERAZİN HİBRİTLERİNİN SENTEZİ VE BİYOLOJİK OLARAK DEĞERLENDİRİLMESİ

İbiş K., Nalbat E., Çalışkan B., Atalay R., Banoğlu E.

VI. Ulusal Farmasötik Kimya Kongresi, İstanbul, Türkiye, 26 - 29 Ağustos 2022, (Özet Bildiri) Sürdürülebilir Kalkınma

22. SELECTIVE OR DUAL INHIBITORS OF INFLAMMATORY PGE2 AND LTB4 BIOSYNTHESIS BY TARGETING mPGES-1 AND FLAP TO INTERVENE WITH INFLAMMATORY DEREGULATION

BANOĞLU E., ÇALIŞKAN B., ERGÜL A. G., GÜR MAZ Z. T., OLĞAÇ A., WERZ O.

The Sixth International Symposium on Pharmaceutical and Biomedical Sciences (ISPBS-6), Gaziantep, Türkiye, 26 - 28 Mayıs 2022, (Özet Bildiri)

23. Discovery of Novel Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitors: A New Modality to Treat Inflammation

Banoğlu E., Çalışkan B., Ergül A. G., Gür Maz Z. T., Kretzer C., Olğaç A., et al.

10th International Drug Chemistry Conference, Antalya, Türkiye, 10 - 13 Mart 2022, (Özet Bildiri)

24. Novel isoxazole- piperazine derivatives inhibit the stemness of HCC cells

NALBAT E., İBİŞ K., ÇALIŞKAN B., BANOĞLU E., ATALAY M. V., ATALAY R.

AASLD-TASL Digital Hepatology Meeting, Ankara, Türkiye, 15 Ocak 2022, ss.5-6, (Tam Metin Bildiri)

25. NOVEL PIPERAZINYL UREA DERIVATIVES AS POTENTIAL FATTY ACID AMIDE HYDROLASE (FAAH) INHIBITORS

TURANLI S., ÇALIŞKAN H. B., GÜR MAZ Z. T., ÇALIŞKAN B., BANOĞLU E.

3rd International Gazi Pharma Symposium Series, 08 Eylül 2021, (Özet Bildiri)

26. Vicinal Diaryl Heterocyclic Compounds with Potential Anticancer Activity

TURANLİ S., ÇALIŞKAN B., AKHAN GÜZELCAN E., GÜNTEKİN ERGÜN S., ATALAY R., BANOĞLU E.

EFMC-ISMC EFMC-YMCS Virtual Poster Session, 09 Eylül 2020, (Özet Bildiri)

27. Synthesis of 3,4-Diaryl-5-methylisoxazoles with Potent Antiproliferative Activity Against a Panel of Human Liver and Breast Cancer Cell Lines

LENGERLİ D., TURANLİ S., ÇALIŞKAN B., AKHAN GÜZELCAN E., NALBAT E., ATALAY R., et al.

EFMC-ISMC EFMC-YMCS Virtual Poster Session, 09 Eylül 2020, (Özet Bildiri) Sürdürülebilir Kalkınma

28. Synthesis of New Vicinal Diaryl Five-Membered Heterocyclic Compounds with Potential Anticancer Activity

TURANLİ S., LENGERLİ D., ÇALIŞKAN B., AKHAN GÜZELCAN E., NALBAT E., ATALAY R., et al.

8th International Drug Chemistry Conference, 27 Şubat - 01 Mart 2020, (Özet Bildiri)

29. Discovery of Multitarget Inhibitors in the Arachidonic Acid Pathway by Targeting FLAP/5-LO/mPGES-1 for Intervention with Inflammatory Deregulation

BANOĞLU E., ÇALIŞKAN B., GÜR MAZ Z. T., OLĞAÇ A., Garscha U., Werz O.

8th International Drug Chemistry Conference, Antalya, Türkiye, 27 Şubat - 01 Mart 2020, (Özet Bildiri)

30. A SMALL MOLECULE INHIBITOR OF TRANSFORMING ACIDICCOILED-COIL PROTEIN 3 (TACC3): A NOVEL THERAPEUTICSTRATEGY FOR THE TREATMENT OF BREAST CANCER

LENGERLİ D., Akbulut O., ÇALIŞKAN B., ŞAHİN Ö., BANOĞLU E.

11th Joint Meeting on Medicinal Chemistry 2019, PRAG, Çek Cumhuriyeti, 27 - 30 Haziran 2019, (Özet Bildiri) Sürdürülebilir Kalkınma

31. Abstract 3871: A novel TACC3 inhibitor as an anti-cancer agent in breast cancer

Akbulut O., LENGERLİ D., Saatci O., Duman E., Seker U., ÇALIŞKAN B., et al.

Experimental and Molecular Therapeutics, 29 Mart - 03 Nisan 2019 Sürdürülebilir Kalkınma

32. A Novel TACC3 inhibitor as an anti-cancer agent in breast cancer

AKBULUT ÇALIŞKAN Ö., LENGERLİ D., ÇALIŞKAN B., BANOĞLU E., ŞAHİN Ö.

30th EORTC-NCI-AACR Symposium, Dublin, İrlanda, 13 - 16 Kasım 2018, (Özet Bildiri)

33. DISCOVERY OF NOVEL 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS BY VIRTUAL SCREENING ANDPHARMACOLOGICAL EVALUATION

OLĞAÇ A., CAROTTI A., Garscha U., Werz O., Macchiarulo A., BANOĞLU E.

22nd European Symposium on Quantitative Structure-Activity RelationshipsTranslational and Health Informatics: Implications for Drug Discovery, 16 - 20 Eylül 2018, (Özet Bildiri)

34. EVOLUTION OF SELECTIVE FLAP INHIBITOR BRP-7 INTO MULTI-TARGET INHIBITOR OF FLAP, 5-LO AND MPGES-1 IN THE ARACHIDONIC ACID PATHWAY

GÜR MAZ Z. T., ÇALIŞKAN B., OLĞAÇ A., GERSTMEIER J., GARSCHA U., WERZ O., et al.

EFMC International Symposium on Medicinal Chemistry, Ljubljana, Slovenya, 2 - 06 Eylül 2018, ss.231, (Özet Bildiri)

35. PROTEIN-LIGAND INTERACTION ANALYSIS THROUGH DOCKING AND MOLECULAR DYNAMIC SIMULATIONS OF KNOWN 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS

OLĞAÇ A., CAROTTI A., Macchiarulo A., BANOĞLU E.

RICT 2018 Interfacing Chemical Biology and Drug Discovery 54th International Conference on Medicinal Chemistry, Strasbourg, Fransa, 4 - 06 Temmuz 2018, (Özet Bildiri)

36. SYNTHESIS, CYTOTOXICITY AND STRUCTURE-ACTIVITYRELATIONSHIPS OF NOVEL ISOXAZOLE DERIVATIVES ASANTICANCER AGENTS

İbiş K., ÇALIŞKAN B., AKHAN GÜZELCAN E., Sinoplu E., ATALAY R., BANOĞLU E.

RICT 2018, 4 - 06 Temmuz 2018, (Özet Bildiri)

37. SYNTHESIS AND ANTIPROLIFERATIVE EVALUATION OF NOVEL ISOXAZOLE-PIPERAZINE HYBRIDS

ÇALIŞKAN B., Sinoplu E., İbiş K., AKHAN GÜZELCAN E., ATALAY R., BANOĞLU E.

RICT 2018, 4 - 06 Temmuz 2018, (Özet Bildiri)

38. SANAL TARAMA VE FARMAKOLOJİK DEĞERLENDİRME YOLUYLA YENİ 5-LİPOKSİJENAZ AKTİVE EDİCİ PROTEİN (FLAP) İNHİBİTÖRÜ BİLEŞİKLERİN KEŞFİ

OLĞAÇ A., CAROTTI A., Garscha U., Werz O., Macchiarulo A., BANOĞLU E.

V. ULUSAL FARMASÖTİK KİMYA KONGRESİ, Erzurum, Türkiye, 28 Nisan - 01 Mayıs 2018, (Özet Bildiri)

39. ANTİLÖKOTRİEN ETKİLİ 1,2,5-TRİSÜBSTİTÜEBENZİMİDAZOL TÜREVLERİNİN GELİŞTİRİLMESİ ÜZERİNDE YAPILAN ÇALIŞMALAR

GÜR MAZ Z. T., ÇALIŞKAN B., GERSTMEIER J., OLĞAÇ A., GARSCHA U., WERZ O., et al.

V. ULUSAL FARMASÖTİK KİMYA KONGRESİ, Erzurum, Türkiye, 28 Nisan - 01 Mayıs 2018, (Özet Bildiri)

40. Discovery of Tyrosinase Inhibitors from Geranium glaberrimum Boiss. Heldr. Using In Vitro and In Silico Methods

Çelikler Ö., ŞENOL DENİZ F. S., ÇALIŞKAN B., GÜR MAZ Z. T., KAHRAMAN A., ERDOĞAN ORHAN İ., et al.

The 4th Mediterranean Symposium on Medicinal and Aromatic Plants (MESMAP-2018), 18 - 22 Nisan 2018, (Özet Bildiri)

41. Discovery and Development of Novel Anti-cancer and Anti-inflammatory Compounds: Medicinal Chemistry Challenges

BANOĞLU E., ÇALIŞKAN B., GÜR MAZ Z. T., OLĞAÇ A., İBİŞ K., Akhan Güzelcam E., et al.

The 4th International Symposium on Pharmaceutical and Biomedical Sciences, Kumamoto, Japonya, 17 Mart 2018, (Özet Bildiri) Sürdürülebilir Kalkınma

42. FROM BATCH TO CONTINUOUS FLOW CHEMISTRY:DOE-ASSISTED OPTIMIZATION OF BENZIMIDAZOL-2-ONESYNTHESIS

GÜR Z. T., MOSTARDA S., PICCINNO A., ÇALIŞKAN B., BANOĞLU E., GIOIELLO A.

2nd International Gazi Pharma Symposium Series, 11 - 13 Ekim 2017, (Özet Bildiri)

43. Developing Multi-target Inhibitors of Arachidonic Acid Pathway Based on the FLAP Inhibitor BRP-7

GÜR Z. T., ÇALIŞKAN B., GERSTMEIER J., OLĞAÇ A., GARSCHA U., WERZ O., et al.

2nd International Gazi Pharma Symposium Series, 11 - 13 Ekim 2017, (Özet Bildiri)

44. Discovery of Novel 5-Lipoxygenase Activating Protein (FLAP) Inhibitors by Virtual Screening

OLĞAÇ A., CAROTTI A., GERSTMEIER J., GARSCHA U., WERZ O., MACCHIARULO A., et al.

2nd International Gazi Pharma Symposium Series, 11 - 13 Ekim 2017, (Özet Bildiri)

45. Discovery of Dual FLAP/mPGES-1 Inhibitors for Intervention with Inflammatory Diseases:Medicinal Chemistry Challenges

BANOĞLU E., ÇALIŞKAN B., GÜR Z. T., OLĞAÇ A.

Turkish Japanese Workshop on Bioorganic Medicinal Chemistry Natural Products, 14 Eylül 2017, (Özet Bildiri)

46. Tirozinaz İnhibitör Etkili Yeni Sinnamik Asit Türevleri

ÇALIŞKAN B., GÜR Z. T., ŞENOL F. S., SHEKFEH S., ERDOĞAN ORHAN İ., BANOĞLU E.

29. Ulusal Kimya Kongresi, Türkiye, 10 - 14 Eylül 2017, ss.452, (Özet Bildiri)

47. Discovery of Novel Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitors Using Structure-Based Virtual Screening.

Shekfeh S., Katrin F., ÇALIŞKAN B., Garscha U., Werz O., BANOĞLU E.

EFMC-ASMC 2017 International Symposium on Advances in Synthetic and Medicinal Chemistry, 27 - 31 Ağustos 2017, (Özet Bildiri)

48. Discovery of Novel 5-Lipoxygenase Activating Protein (FLAP) Inhibitors by Combined Ligand- and Structure-Based Virtual Screening

OLĞAÇ A., CAROTTI A., GERSTMEIER J., GARSCHA U., WERZ O., MACCHIARULO A., et al.

EFMC-ASMC’xx17 EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry, 27 - 31 Ağustos 2017, (Özet Bildiri)

49. Bioisosteric Tuning of FLAP Inhibitor BRP-7 Towards a More Potent Antiinmlammatory Agent with Multiligand Inhibitor Properties in the Arachidonic Acid (AA) Pathway

GÜR Z. T., ÇALIŞKAN B., OLĞAÇ A., GERSTMEIER J., GARSCHA U., WERZ O., et al.

EFMC-ASMC’xx17 EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry, 27 - 31 Ağustos 2017, (Özet Bildiri)

50. Araşidonik asit yolağında çoklu ligand (FLAP/5-LO/mPGES-1) özellikte inhibitör etkili BRP-7 türevlerinin geliştirilmesi

BANOĞLU E., GÜR Z. T., ÇALIŞKAN B., GERSTMEIER J., OLĞAÇ A., GARSCHA U., et al.

1. Anadolu Üniversitesi Eczacılık Sempozyumu, Eskişehir, Türkiye, 1 - 02 Haziran 2017, ss.10, (Özet Bildiri)

51. 5-Sübstitüe-Benzimidazol Türevi Bileşiğin Farelerde Analjezik ve Antienflamatuvar Aktivite Tarama Çalışması

Göker S., HAN S., ÇALIŞKAN B., BANOĞLU E., ULUDAĞ M. O.

3rd International Convention of Pharmaceuticals and Pharmacies, İstanbul, Türkiye, 26 - 29 Nisan 2017, ss.732, (Özet Bildiri)

52. Diarilpirazol Türevi Bileşiğin (BRP-42) Analjezik ve Antienflamatuvar Aktivitesi Üzerinde Çalışmalar

GÖKER G., HAN S., ÇALIŞKAN B., BANOĞLU E., ULUDAĞ M. O.

3rd International Convention of Pharmaceuticals and Pharmacies, İstanbul, Türkiye, 26 - 29 Nisan 2017, ss.752, (Özet Bildiri)

53. İzoksazol Türevi Bileşiklerin in-vivo Analjezik ve Antienflamatuvar Aktivitesi Üzerinde Çalışmalar

Örnek Ö., HAN S., ÇALIŞKAN B., BANOĞLU E., ULUDAĞ M. O.

3rd International Convention of Pharmaceuticals and Pharmacies, İstanbul, Türkiye, 26 - 29 Nisan 2017, ss.738, (Özet Bildiri)

54. Anticancer activity of novel benzimidazole derivatives against MCF-7 cancer cells

ÖZDEMİR A., UZUNOĞLU S., ÇALIŞKAN B., BANOĞLU E., ARK M.

Experimental Biology 2017, Chicago, 22 - 26 Nisan 2017, cilt.31, (Özet Bildiri) Sürdürülebilir Kalkınma

55. Anticancer activity of novel benzimidazole derivatives against MCF-7 cancer cells

ÖZDEMİR A., Uzunoglu S., ÇALIŞKAN B., BANOĞLU E., ARK M.

Experimental Biology Meeting, Illinois, Amerika Birleşik Devletleri, 22 - 26 Nisan 2017, cilt.31, (Özet Bildiri) Sürdürülebilir Kalkınma

56. Structure Guided Design of Novel Isoxazole and Benzimidazole Derivatives as Potent 5 Lipoxygenase 5 LO and 5 LO Activating Protein FLAP Inhibitors

OLĞAÇ A., CAROTTI A., WERZ O., BANOĞLU E., MACCHIARULO A.

XXIV National Meeting in Medicinal Chemistry, Perugia, İtalya, 11 - 14 Eylül 2016, (Özet Bildiri)

57. Evias Web Services Cloud Based Drug Discovery Platform

OLĞAÇ A., BUDAK G., OLĞAÇ S., NUTI R., CAROTTI A., BANOĞLU E.

21st European Symposium on Quantitative Structure-Activity Relationship, Verona, İtalya, 4 - 08 Eylül 2016, (Özet Bildiri)

58. Novel BRP 7 Derivatives Targeting FLAP Potent Inhibitors of Leukotriene Biosynthesis

GÜR Z. T., ÇALIŞKAN B., GERSTMEIER J., GARSCHA U., OLĞAÇ A., WERZ O., et al.

3rd EFMC Young Medicinal Chemist Symposium, Manchester, Birleşik Krallık, 1 - 02 Eylül 2016, (Özet Bildiri)

59. Exploratıon of the Chemıcal Space Around C 5 Posıtıon Of The Benzimidazole Nucleus in BRP 7 Towards More Potent Inhıbıtors of Human 5 Lıpoxygenase Actıvatıng Proteın FLAP

GÜR Z. T., ÇALIŞKAN B., GERSTMEIER J., OLĞAÇ A., NIKELS F., WERZ O., et al.

EFMC International Symposium on Medicinal Chemistry 2016, Manchester, Birleşik Krallık, 28 Ağustos - 01 Eylül 2016, (Özet Bildiri)

60. Discovery of 4 5 Diarylisoxazol 3 Carboxylic Acid Skeleton as a Novel Chemotype for Inhibition of 5 Lipoxygenase Activating Proteın FLAP

ÇALIŞKAN B., ÇELİKOĞLU E., GERSTMEIER J., VOELKER S., GARSCHA U., OLĞAÇ A., et al.

EFMC International Symposium on Medicinal Chemistry 2016, Manchester, Birleşik Krallık, 28 Ağustos - 01 Eylül 2016, (Özet Bildiri)

61. DISCOVERY OF 4 5 DIARYLISOXAZOL 3 CARBOXYLIC ACID SKELETON AS A NOVEL CHEMOTYPE FOR INHIBITION OF 5 LIPOXYGENASE ACTIVATING PROTEIN FLAP

ÇALIŞKAN B., çelikoğlu e., gerstmeier j., voelker s., garscha u., OLĞAÇ A., et al.

EFMC International Symposium on Medicinal Chemistry, Manchester, Birleşik Krallık, 28 Ağustos - 01 Eylül 2016, (Özet Bildiri)

62. EXPLORATION OF THE CHEMICAL SPACE AROUND C 5 POSITION OF THE BENZIMIDAZOLE NUCLEUS IN BRP 7 TOWARDS MORE POTENT INHIBITORS OF HUMAN 5 LIPOXYGENASE ACTIVATING PROTEIN FLAP

GÜR Z. T., ÇALIŞKAN B., Gerstmeier J., OLĞAÇ A., nikels F., werz o., et al.

EFMC International Symposium on Medicinal Chemistry, Manchester, Birleşik Krallık, 28 Ağustos - 01 Eylül 2016, (Özet Bildiri)

63. Structure Guided Design of Novel Isoxazole and Benzimidazole Derivatives as Potent FLAP and 5 LO Inhibitors

OLĞAÇ A., CAROTTI A., BANOĞLU E., MACCHIARULO A.

IBSS'2016 Resources and Techniques in Computational Drug Discovery, Fas, 23 - 26 Mayıs 2016, (Özet Bildiri)

64. Evias Cloud Based Drug Discovery Platform

OLĞAÇ A., BUDAK G., OLĞAÇ S., NUTI R., CAROTTI A., BANOĞLU E.

High-Performance Modelling and Simulation for Big Data Applications - Management Committee & Working Group Meeting, Dublin, İrlanda, 25 - 26 Nisan 2016, (Özet Bildiri)

65. STRUCTURE BASED DESIGN AND SYNTHESIS OF NOVEL BRP 7 DERIVATIVES BEARING C 5 POLAR SUSBTITUENTS AS POTENT FLAP INHIBITORS

GÜR Z. T., OLĞAÇ A., Gerstmeiner J., Macchiarulo A., Werz O., ÇALIŞKAN B., et al.

GPSS 2015, Antalya, Türkiye, 12 - 15 Kasım 2015

66. Structure-Guided Design of Novel Isoxazole and Benzimidazole Derivatives as Potent FLAP and 5-LO Inhibitors: Insights from Molecular Dynamics Simulations

OLĞAÇ A., CAROTTI A., WERZ O., MACCHIARULO A., BANOĞLU E.

1st International Gazi Pharma Symposium Series, 12 - 15 Kasım 2015, (Özet Bildiri)

67. İzole Sfenoid Sinüs Cerrahisi 40 vakalık serimiz

ERAVCI F. C., CEYLAN A., İLERİ F., USLU S. S., YILMAZ M., BANOĞLU E., et al.

37. ULUSAL KBB BBC KONGRESİ, Türkiye, 28 Ekim - 01 Kasım 2015, (Tam Metin Bildiri)

68. Structure-Based Design And Synthesis Of Novel Isoxazole And Benzimidazole Derivatives As Potent FLAP and 5-LO Inhibitors: Insights From Molecular Dynamics Simulations

OLĞAÇ A., CAROTTI A., WERZ O., BANOĞLU E., MACCHIARULO A.

Summer School on Drug Design in September in Vienna 2015, Viyana, Avusturya, 20 - 25 Eylül 2015, (Özet Bildiri)

69. Structure-Based Design and Synthesis of Novel BRP-7 Derivatives as Potent FLAP Inhibitors: Insights from MolecularDynamics Simulations.

OLĞAÇ A., GÜR Z. T., CAROTTI A., ÇALIŞKAN B., GERSTMEIER J., WERZ O., et al.

EFMC International Symposium on Medicinal Chemistry, LİZBON, Portekiz, 7 - 11 Eylül 2014, ss.162, (Özet Bildiri)

70. Towards Pharmacophore and Docking based Virtual Screening of Human P2Y12 Receptor Antagonists with the Homology modeled Protein Structure

EREN G., BANOĞLU E.

20th EuroQSAR, Understanding Chemical-Biological Interactions, St. Petersburg, Rusya, 31 Ağustos - 04 Eylül 2014, (Özet Bildiri)

71. Computer Aided Drug Design Targeting 5LO and FLAP

OLĞAÇ A., CAROTTI A., WERZ O., MACCHIARULO A., BANOĞLU E.

The First Technical Meeting on High-Throughput Molecular Dynamics 2013, 7 - 08 Kasım 2013, (Özet Bildiri)

72. New 4,5-Diarylisoxazole Derivatives as Novel Inhibitors of Human 5-Lipoxygenase (5-LO)

ÇALIŞKAN B., LUDERER S., GERSTMEIER J., EREN G., WERZ O., BANOĞLU E.

EFMC-ISMC 2012, XXIInd International Symposium on Medicinal Chemistry, Berlin, Almanya, 2 - 06 Eylül 2012, (Özet Bildiri)

73. From Molecular Docking to 3D-Quantitative Structure-Activity Relationships (3D-QSAR): Insights into the Binding Mode of 5-Lipoxygenase Inhibitors

EREN G., MACCHIARULO A., BANOĞLU E.

EFMC-ISMC 2012, XXIInd International Symposium on Medicinal Chemistry, Berlin, Almanya, 2 - 06 Eylül 2012, (Özet Bildiri)

74. New Isoxazole Derivatives as Novel Inhibitors of 5-Lipoxygenase

ÇALIŞKAN B., LUDERER S., EREN G., WERZ O., BANOĞLU E.

4th International Symposium on Advanced in Synthetic and Medicinal Chemistry, St. Petersburg, Rusya, 21 - 25 Ağustos 2011, (Özet Bildiri)

75. From Molecular Docking to 3D-Quantitative Structure-Activity Relationships (3D-QSAR): Insights into the Binding Mode of 5-Lipoxygenase Inhibitors

EREN G., MACCHIARULO A., BANOĞLU E.

VIII EWDD, Eighth European Workshop in Drug Design, Siena, İtalya, 22 - 28 Mayıs 2011, (Özet Bildiri)

76. An Approach to Combined Ligand- and Structure-Based Virtual Screening and QSAR Studies for Determining Novel 5-Lipoxygenase Inhibitors

EREN G., BANOĞLU E.

IMMPC-ISPC Joint Meeting, 4th International Meeting on Medicinal and Pharmaceutical Chemistry, 6th International Symposium on Pharmaceutical Chemistry, Ankara, Türkiye, 30 Eylül - 02 Ekim 2010, (Özet Bildiri)